Drug Trial Radar · NCT03926130
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,158
Actual
Start
Jul 23, 2019
Primary completion
Aug 23, 2023
Study completion Oct 2, 2023
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Apr 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Conditions
- Crohn's Disease
Interventions
MirikizumabDrug
Administered IV
MirikizumabDrug
Administered SC
UstekinumabDrug
Administered IV
UstekinumabDrug
Administered SC
PlaceboDrug
Administered IV
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)Time frame: Week 12 to Week 52
- Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)Time frame: Week 12 to Week 52
Locations
580 sites in 34 countries. Site status is shown where the registry gives one.
University of Alabama-The Kirklin Clinic
Birmingham, Alabama
Digestive Health Specialists
Dothan, Alabama
Lakeview Clinical Research
Guntersville, Alabama
Care Access Research - Tuscaloosa
Tuscaloosa, Alabama
Research Solutions of Arizona
Litchfield Park, Arizona
Central Arizona Medical Associates, PC
Mesa, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Phoenix, Arizona
Reliance Research
Scottsdale, Arizona
Synexus Site Network
Tempe, Arizona
inSite Digestive Health Care
Arcadia, California
B G Clinical Research, Inc.
Encinitas, California
Care Access - Gilroy
Gilroy, California
Newport Huntington Med Grp
Huntington Beach, California
Om Research, LLC
Lancaster, California
GastroIntestinal Biosciences Clinical Trials
Los Angeles, California
California Medical Research Associates
Northridge, California
University of California Irvine
Orange, California
inSite Digestive Health Care
Pasadena, California
Care Access Research - San Jose
San Jose, California
Wolverine Clinical Trials, LLC
Santa Ana, California
Fomat Medical Research, Inc.
Thousand Oaks, California
Connecticut Gastroenterology
Manchester, Connecticut
IMR of South Florida
Aventura, Florida
Gastroenterology Consultants of Clearwater
Clearwater, Florida
West Central Gastroenterology d/b/a Gastro Florida
Clearwater, Florida
Inpatient Research Clinic
Hialeah, Florida
Doral Medical Research
Hialeah, Florida
C2 Research Center, LLC
Jacksonville, Florida
I.H.S. Health, LLC
Kissimmee, Florida
Central Florida Gastro Research
Kissimmee, Florida
Florida Research Institute
Lakewood Rch, Florida
Wellness Clinical Research
Lehigh Acres, Florida
Columbus Clinical Services, LLC
Miami, Florida
Infinite Clinical Research
Miami, Florida
Nickalus Children's Hospital Research Institute
Miami, Florida
Research Associates of South Florida, LLC
Miami, Florida
SaludMax Medical Corp
Miami, Florida
Ezy Medical Research
Miami, Florida
Coral Research Clinic Corp
Miami, Florida
Goji Group - Research Trials Group
Miami Lakes, Florida
Showing 40 of 580 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.